SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
Drug Development
Verona, Daiichi Sankyo, AstraZeneca and Kodiak Score Big Wins in Key Diseases
The week started off with a clinical bang for Verona Pharma, Kodiak, AstraZeneca and Daiichi Sankyo with wins in COPD, lung cancer and macular edema respectively.
August 9, 2022
 · 
3 min read
 · 
Vanessa Doctor, RN
Steve Worland/courtesy of eFFECTOR
Drug Development
“Practice-Changing” Trial Introduces New Standard of Care for Breast Cancer Patients
The DESTINY-Breast04 trial introduces a new option for breast cancer diagnosis – HER2-low. The trial data received a standing ovation from thousands of oncologists at this year’s ASCO meeting.
July 27, 2022
 · 
6 min read
 · 
Kaley Lefevre
Sarah Silbiger/Getty Images
Drug Development
FDA Hands Out Regulatory Nods to Novartis, AstraZeneca, HOOKIPA
Daiichi-Sankyo and AstraZeneca’s sBLA for HER2 directed Enhertu accepted by FDA. Novartis gets BLA acceptance for MS biosimilar. HOOKIPA’s IND for prostate cancer immunotherapy candidate accepted
July 25, 2022
 · 
4 min read
 · 
Tristan Manalac
Policy
Battle of the Patents: Daiichi Sankyo, Seagen, Alnylam, CureVac, Pfizer, BioNTech & Moderna
The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here’s a look at recent biopharma patent disputes.
July 20, 2022
 · 
3 min read
 · 
Mark Terry
Researchers Stumble Upon Potential Key to Slow DMD
Research scientists have found that a colony-stimulating factor 1 receptor inhibitor may also be a potential treatment for Duchenne muscular dystrophy.
July 5, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
AstraZeneca, Daiichi Sankyo Move the Bar in Metastatic Breast Cancer
Data presented at the ASCO meeting this weekend show that treatment with Enhertu demonstrated a 49% improvement in median overall survival by more than six months.
June 6, 2022
 · 
3 min read
 · 
Alex Keown
Courtesy of Getty Images
Drug Development
Celebrities are Bringing Awareness to Breast Cancer
Celebrities’ struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health’s elacestrant are on the horizon.
May 20, 2022
 · 
3 min read
 · 
Hayley Shasteen
Drug Development
Mersana Enters Busy Gastric Cancer Space with Orphan Drug Designation
On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
May 19, 2022
 · 
2 min read
 · 
Hayley Shasteen
Courtesy of Getty Images
Drug Development
AstraZeneca and Daiichi Sankyo Move into Earlier Treatment Space with Enhertu
AstraZeneca and Daiichi Sankyo’s breast cancer therapeutic Enhertu received supplemental approval for an earlier form of breast cancer from the U.S. Food and Drug Administration.
May 5, 2022
 · 
2 min read
 · 
Hayley Shasteen
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
Drug Development
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
September 11, 2023
 · 
30 min read
Drug Development
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
September 10, 2023
 · 
11 min read
Drug Development
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial
September 10, 2023
 · 
11 min read
Pharm Country
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
September 10, 2023
 · 
8 min read
Drug Development
DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers
September 7, 2023
 · 
4 min read
Pharm Country
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLC
August 16, 2023
 · 
5 min read
Pharm Country
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML
August 9, 2023
 · 
17 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
July 27, 2023
 · 
26 min read
Drug Development
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
July 27, 2023
 · 
26 min read
FDA
VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML
July 20, 2023
 · 
20 min read
Load More